I think a great deal depends on your definition of eminent. For a vaccine that's been in development for decades, I'd say an expected approval in the next 3 to 4 months could be called eminent. Certainly, it's not happening tomorrow, I'd put the odds of happening this month at no more than 10%, but next month could be 40% or higher, by May might be 80% and by June 95% IMHO of course.
The peer reviewed article in Nature may come sooner, or later, if we've learned anything about peer reviewed Journal articles it's that you really can't predict when they'll happen, we just know that it's in peer review.
This is not something that only happens to NWBO, I have a position in AVLX and they too have been holding on for ages for a peer reviewed article, and no investor seems to know what Journal it will appear in. At least we know that Nature is where we'll see the article.
Gary
Bullish
Market Data 
Markets 
AI
